Several animal experiments have shown beneficial effects of G-CSF therapy, including adriamycin nephropathy, by reductions in the number of atrophic sites, the severity of fibrosis, and the glomerulosclerosis rate [27]. Here, CSF3 is linked to glomerulosclerosis.